MRK logo

MRK
Merck & Co Inc

25,722
Mkt Cap
$275.09B
Volume
10.03M
52W High
$125.14
52W Low
$75.40
PE Ratio
31.35
MRK Fundamentals
Price
$111.38
Prev Close
$113.41
Open
$113.90
50D MA
$115.78
Beta
0.32
Avg. Volume
9.33M
EPS (Annual)
$7.28
P/B
6.00
Rev/Employee
$865,680.00
$299,786.82
Loading...
Loading...
News
all
press releases
Regeneron’s Drug Combo Fails To Prove Superiority Over Merck’s Keytruda In Melanoma
The company tested its experimental drug fianlimab, combined with its approved medicine Libtayo, against Merck’s Keytruda in the trial.
Stocktwits·1d ago
News Placeholder
More News
News Placeholder
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Zacks·3d ago
News Placeholder
Will Keytruda Continue to Aid MRK's Growth in 2026 After a Strong Q1?
Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.
Zacks·4d ago
News Placeholder
Moderna's Revenues See Strong International Momentum in Q1 Earnings
MRNA's Q1 revenues soar 260% on strong international vaccine sales, while cost cuts and new EU approvals support its broader growth strategy.
Zacks·5d ago
News Placeholder
Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstracts across over 25 types of cancer from the companys comprehensive oncology portfolio and pipeline will be presented at the 2026 American Society of Clinical Oncology...
Business Wire·5d ago
News Placeholder
The Zacks Analyst Blog UnitedHealth, Merck & Co., Qualcomm, EVI and Optex
UNH, MRK and QCOM drew focus as analysts highlighted growth drivers, pipeline strength and expanding AI and automotive opportunities.
Zacks·5d ago
News Placeholder
Top Research Reports for UnitedHealth, Merck & Qualcomm
UnitedHealth, Merck and QUALCOMM lead Zacks' top research picks as analysts highlight growth drivers, earnings trends and key risks.
Zacks·6d ago
News Placeholder
Merck Stock Down 7% in a Month: Should Investors Hold or Exit?
Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.
Zacks·6d ago
News Placeholder
Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the publication of work describing the large-scale synthesis of enlicitide decanoate, the companys...
Business Wire·10d ago
News Placeholder
Darzalex, Erleada & New Drugs Keep J&J's Oncology Engine Charged in Q1
Darzalex and new launches fuel J&J's 17.8% oncology sales growth in Q1 as the company targets $50B in cancer sales by 2030.
Zacks·10d ago
<
1
2
...
>

Latest MRK News

View
Top Discussions